The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Improved Biomarkers and Clinical Outcome Measures, 2020Development of a Non-Invasive Ophthalmic Diagnostic for Parkinson’s Disease
Study Rationale:
Currently, diagnosis of Parkinson’s disease relies on extensive neurological and physical examinations. A hallmark of Parkinson's is misfolded alpha-synuclein that forms aggregates... -
Therapeutic Pipeline Program, 2020Pre-clinical Development of Compounds that Modulate Mitophagy through Regulation of the Mitochondrial GTPase Miro1
Study Rationale:
Evidence indicates that mitochondrial dysfunction is a significant contributor to Parkinson’s disease, with the majority of patients exhibiting a shared defect in the processing of... -
Therapeutic Pipeline Program, 2020Pregnenolone for the Treatment of L-DOPA-induced Dyskinesia in Parkinson's disease
Study Rationale:
Neurosteroids are substances that occur naturally in the brain and help regulate and modulate the activity of brain cells. In previous studies, the investigators demonstrated that... -
Therapeutic Pipeline Program, 2020Target Validation Studies for the Discovery of Novel Small Molecule Therapeutics with the Potential to Modify Disease Outcome by Inhibiting Bacterial Amyloid Protein-induced Alpha-synuclein Aggregation and Associated Neuronal Toxicity
Study Rationale:
Patients with Parkinson’s disease frequently report serious gastrointestinal (GI) symptoms, most commonly constipation, which are not well treated with currently available medicine... -
Improved Biomarkers and Clinical Outcome Measures, 2020RT-QuIC Testing of Misfolded Alpha-synuclein in S4 Study Samples
Study Rationale:
The protein alpha-synuclein is vital to normal brain function. In Parkinson's disease, alpha-synuclein misfolds, forming aggregates, or clumps, that impair the ability of brain cells... -
Improved Biomarkers and Clinical Outcome Measures, 2020Quantification of S129 Phosphorylated Alpha-Synuclein Using the AlphaLISA Immunoassay Platform
Study Rationale:
In Parkinson's, there remains an unmet need for biomarkers to track disease progression and efficacy of potential therapies. This team of investigators is focused on fluid-based...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.